Brain Cancer

Breaking

Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD FDA Approves Guardant360 CDx Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer RAPS Euro Convergence 2026: Regulatory News - Day 1 Roundup

NewsApr 23, 2026

Alphamab Oncology JSKN016 TROP2/HER3 Bispecific ADC Shows Promise for HER2-Negative Breast Cancer at ASCO 2026

Alphamab Oncology presents clinical data for JSKN016, a novel TROP2/HER3 bispecific ADC targeting HER2-negative breast cancer at ASCO 2026 conference.

Dr. Yuna Park

News by Topic

More News Topics

Press Releases

Analysis by Topic

More Analysis Topics

Whitepapers

Browse

By Region

Directory

By Region

For Suppliers

For Brands

Resources

Popular Topics

More Topics

Browse

About Us

Get in Touch

Quick Actions

Recent Searches

Popular Topics

Suggestions

Alphamab Oncology JSKN016 TROP2/HER3 Bispecific ADC Shows Promise for HER2-Negative Breast Cancer at ASCO 2026